NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has four programs in active clinical development.
Corporate Profile
Nov 30, 2023 11:21 PM EST
Corporate Presentation
NGM Bio Corporate Presentation November 2023
NGM Bio Corporate Presentation November 2023
Explorer Series 1: NGM Bio’s Discovery Engine
Explorer Series 1: NGM Bio’s Discovery Engine
Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs
Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs
Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate
Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate
Explorer Series 4: NGM621
Explorer Series 4: NGM621
CATALINA Topline Results Presentation
CATALINA Topline Results Presentation
Data Provided by Refinitiv. Minimum 15 minutes delayed.
